Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0020)
Name
Ethoxyquin
Synonyms
ethoxyquin; 91-53-2; 6-Ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline; Ethoxyquine; Santoquin; Santoquine; Niflex; Antioxidant EC; Santoflex A; Santoflex AW; Stop-Scald; Dawe's nutrigard; Nix-Scald; Nocrack AW; Quinol ED; (-)-Normetazocine; Permanax 103; Aries Antox; Amea 100; Niflex D; Antage AW; Nocrac AW; Alterungsschutzmittel EC; Ethoxyquin [ISO]; Ethoxychin; Quinoline, 6-ethoxy-1,2-dihydro-2,2,4-trimethyl-; Usaf B-24; Santoquine (VAN); 1,2-Dihydro-6-ethoxy-2,2,4-trimethylquinoline; 6-Ethoxy-1,2-dihydro-2,2,4-trimethylquinoline; Santoflex; 6-ethoxy-2,2,4-trimethyl-1H-quinoline; NSC-6795; 1,2-Dihydro-2,2,4-trimethyl-6-ethoxyquinoline; 2,2,4-Trimethyl-6-ethoxy-1,2-dihydroquinoline; EMQ; EQ; 63301-91-7; DTXSID9020582; CHEBI:77323; 9T1410R4OR; 6-(ethyloxy)-2,2,4-trimethyl-1,2-dihydroquinoline; CAS-91-53-2; NCGC00016348-02; E324; DTXCID70582; Ethoxychin [Czech]; Ethyl 2,2,4-trimethyl-1,2-dihydro-6-quinolinyl ether; Caswell No. 427D; CCRIS 2513; HSDB 400; EINECS 202-075-7; 6-ETMDQ; EPA Pesticide Chemical Code 055501; SantoquinEQ; UNII-9T1410R4OR; AI3-17715; Prestwick_1064; Spectrum_001214; ETHOXYQUIN [MI]; ETHOXYQUIN [FCC]; Prestwick0_000765; Prestwick1_000765; Prestwick2_000765; Prestwick3_000765; Spectrum2_001384; Spectrum3_001423; Spectrum4_000404; Spectrum5_001530; ETHOXYQUIN [HSDB]; ETHOXYQUIN [MART.]; SCHEMBL21601; BSPBio_000810; BSPBio_003126; KBioGR_000668; KBioSS_001694; MLS001055488; BIDD:GT0822; DivK1c_000183; SPECTRUM1500998; SPBio_001368; SPBio_002749; BPBio1_000892; CHEMBL172064; HMS500J05; KBio1_000183; KBio2_001694; KBio2_004262; KBio2_006830; KBio3_002346; NSC6795; NINDS_000183; HMS1570I12; HMS1923K03; HMS2097I12; HMS3714I12; 1,2,4-trimethyl-6-ethoxyquinoline; HY-B1425; NSC 6795; 6-Ethoxy-1,2,4-trimethylquinoline; Tox21_110388; Tox21_201336; Tox21_300328; CCG-39002; Ethoxyquin, >=75% (capillary GC); MFCD00023883; s5369; STK772149; AKOS000121441; CS-8200; IDI1_000183; NCGC00016348-01; NCGC00016348-03; NCGC00016348-04; NCGC00016348-05; NCGC00016348-06; NCGC00016348-07; NCGC00016348-08; NCGC00016348-09; NCGC00016348-15; NCGC00090792-01; NCGC00090792-02; NCGC00090792-03; NCGC00090792-04; NCGC00090792-05; NCGC00254395-01; NCGC00258888-01; AC-11742; AS-14741; SMR000686069; Ethoxyquin, Vetec(TM) reagent grade, 75%; WLN: T66 BM CHJ C1 C1 E1 HO2; E 324; E0237; FT-0621107; FT-0673108; 2,4-Trimethyl-6-ethoxy-1,2-dihydroquinoline; 6-Ethoxy-2,4-trimethyl-1,2-dihydroquinoline; EN300-21213; Ethoxyquin, PESTANAL(R), analytical standard; F85585; 2,2, 4-Trimethyl-6-ethoxy-1,2-dihydroquinoline; 6-Ethoxy-1, 2-dihydro-2,2,4-trimethylquinoline; 6-Ethoxy-1,2-dihydro-2,2,4-trimethyl-Quinoline; 6-Ethoxy-2,2,4-trimethyl-1, 2-dihydroquinoline; A843964; SR-01000854319; J-010251; Q1657816; SR-01000854319-2; W-100306; BRD-K56792340-001-05-8; Z104494382; 6-Ethoxy-1,2-dihydro-2,2,4-trimethylquinoline, 9CI, 8CI; A10AE280-05F4-4846-ACAE-D565B0D263A2; Ethyl 2,2,4-trimethyl-1,2-dihydro-6-quinolinyl ether #; 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLIN-6-YL ETHYL ETHER

    Click to Show/Hide
Structure
Formula
C14H19NO
IUPAC Name
6-ethoxy-2,2,4-trimethyl-1H-quinoline
Canonical SMILES
CCOC1=CC2=C(C=C1)NC(C=C2C)(C)C
InChI
InChI=1S/C14H19NO/c1-5-16-11-6-7-13-12(8-11)10(2)9-14(3,4)15-13/h6-9,15H,5H2,1-4H3
InChIKey
DECIPOUIJURFOJ-UHFFFAOYSA-N
PubChem CID
3293
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Cardiomyopathy ICD-11: BC43
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model hCMs (Human cardiomyocytes)
In Vivo Model
DOX (D1515, Sigma-Aldrich, St Louis, MO, USA; 6 mg/kg, dissolved in distilled water) was administrated to C57BL/6J Male mice (8-10 weeks old, 21-24 g) via the tail vein on days 0, 2, and 4.Ethoxyquin(E0237, Tokyo Chemical Industry, Tokyo, Japan; 100 umol/kg, once a day) was orally administrated every day from days 0 to 14. Ethoxyquinwas dissolved in polyethylene glycol (PEG; 28214-05, Nacalai Tesque, Kyoto, Japan,ethoxyquin10 uL in 990 uL PEG), and the solution was then diluted in the same amount of normal saline (873311, Otsuka Pharmaceutical, Tokyo, Japan).

    Click to Show/Hide
Response regulation The inhibitory action of ethoxyquin against GPx4-deficient ferroptosis and its therapeutic efficacy against DOX-induced cell death in cultured cardiomyocytes and cardiotoxicity in a murine model of doxorubicin-induced cardiomyopathy (DIC).
References
Ref 1 Ethoxyquin is a Competent Radical-Trapping Antioxidant for Preventing Ferroptosis in Doxorubicin Cardiotoxicity. J Cardiovasc Pharmacol. 2022 Nov 1;80(5):690-699. doi: 10.1097/FJC.0000000000001328.